

2022 Oregon Cardiovascular Symposium
May 13th-14th 2022 | Hybrid
Portland, Oregon

Target Audience

This activity is designed for an audience of Physicians, Nurses, Nurse Practitioners, Physician Assistants, and Pharmacists

Learning Objectives

Upon completion of the educational activity, participants should be able to:

- Identify the patient and institution specific features favoring anatomic or functional assessment of stable and unstable coronary disease.
- Determine whether patients are low, intermediate or high risk as defined in the 2021 ACC/AHA guidelines in both stable and unstable contexts.
- Identify the benefits and limitations in anatomic and functional risk stratification of coronary disease.
- Develop patient and institution specific strategies for anatomic and functional coronary disease risk stratification.
- Describe which patients are most likely to benefit from a rhythm-control strategy.
- Identify the benefits associated with atrial fibrillation ablation.
- Identify new blood pressure goals for select populations.
- Identify first line blood pressure agents recommended for hypertension management.
- Identify the mitral valve pathology that is best treated with mitral valve replacement.
- Determine the risk and benefits of surgical mitral valve replacement.
- Determine the risk and benefits of the emerging therapy of transcatheter mitral valve replacement.
- Develop strategies to talk to patients about exercise programs, 3) understand the physiologic targets of new weight loss medications and cardiovascular outcomes.
- Determine what CPET's value is for patients seen in a general cardiac practice.
- Identify the role of routine CPET in specific patient populations.
- Determine pathologic vs non pathologic response in different patient populations- from a patient with unknown cause of dyspnea to a competitive athlete.
- Discuss the different forms of cardiac amyloidosis.
- Identify the appropriate imaging and laboratory tests for the diagnosis of transthyretin amyloidosis.
- Discuss the forms of medical treatment for TTR amyloidosis.
- Identify the cardiovascular impacts of elevated triglyceride levels.
- Identify novel therapies used for the treatment of hypertriglyceridemia.

Criteria for Success

Statements of credit will be awarded based on the participant's attendance. A statement of credit will be available upon completion of an online evaluation/claim credit form available at:

akhcme.com/or-acc

Please claim your credit by June 15th, 2022

If you have questions about this CE activity, please contact AKH Inc at byron@akhcme.com.



CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Oregon Chapter of the American College of Cardiology. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 19.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 19.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 19.0 contact hours.

Nurses Credit

19.0 ANCC contact hours

Physician Assistants



AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 19.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners



This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Oregon Chapter of the American College of Cardiology Education Foundation AKH Inc., Advancing Knowledge in

Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 19.0 contact hour(s) (which includes XX hour(s) of pharmacology).



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 19.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Commercial Support

There is no commercial support for this activity.

DISCLOSURES		
Name	Relationship	Commercial Interest
Jonathan Piccini, MD (faculty)	Consultant	Abbott, Abbvie, AbLacoon, Altathera, ARCA Biopharma, Biotronik, Boston Scientific, Bristol Myers Squibb, LivaNova, Medtronic, Milestone, ElectroPhysiology Frontiers, Pfizer, Sanofi, Philips, Up-to-Date
	Researcher	National Heart, Lung and Blood Institute, National Institutes of Aging, Abbott, American Heart Association, The Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, iRhythm, Philips
Firas Zahr, MD (faculty)	Consultant	Medtronic, Edwards
	Researcher	Medtronic, Edwards
Martha Gulati, MD (faculty)	N/A	Nothing to Disclose
Scott Chadderdon, MD (faculty)	Consultant	Edwards Lifesciences, Medtronic, Inc
Karol Watson, MD (faculty)	Consultant	Amari, Amgen, Boehringer-Ingelheim, Esperon, Novartis, Lilly
	Speaker	Boehringer-Ingelheim
Pam Taub, MD (faculty)	Consultant	Amarin, Amgen, Bayer, Boehringer-Ingelheim, Esperion, Medtronic, Novartis, Novo-Nordisk, Sanofi
	Stocks	Preventive Cardiology
Marcelo Di Carli, MD (faculty)	Researcher	Gilead Sciences

Gregg Fonarow, MD (faculty)	Consultant	Amgen, Bayer, Janssen, Medtronic, Novartis, Merck, Cytokinetics, AstraZeneca, Abbott
Laurence Sperling, MD (faculty)	N/A	Nothing to Disclose
Alan Morasch, CAE (planner)	N/A	Nothing to Disclose
Matthew Slater, MD (faculty)	N/A	Nothing to Disclose
Andrew Tsen, MD (faculty)	N/A	Nothing to Disclose
Jayne Mitchell, ANP-BC (faculty)	N/A	Nothing to Disclose
Meagan Wasfy, MD MOH (faculty)	N/A	Nothing to Disclose
Sheldon Litwin, MD (faculty)	Consultant	Axon Therapeutics, CVRx
Gorav Ailawadi, MD (faculty)	Consultant	Edwards, Medtronic, Abbott, Gore, Admedus, Cryolife, Ethicon
Yader Sandoval, MD (faculty)	N/A	Nothing to Disclose
Colter Wichern, MD OHSU Fellow (faculty)	N/A	Nothing to Disclose
Omar Sheikh, MD OSHU Fellow (faculty)	N/A	Nothing to Disclose
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer)	N/A	Nothing to Disclose
Dorothy Duffy, RPh (planner/reviewer)	N/A	Nothing to Disclose
Broc Pollinger, MSW, LSW, OSW-C, (planner/reviewer)	N/A	Nothing to Disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to Disclose
AKH Inc Staff and Planners	N/A	Nothing to Disclose
Oregon Chapter of ACC Staff and Planners	N/A	Nothing to Disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.